STAFF BOARD
Article
CHAIRMAN
Virginia Hernández Corredoira
EDITOR IN CHIEF
Manuela Velázquez Prieto
Jaime E. Poquet Jornet
MARKETING MANAGER
EDITORIAL BOARD
Ramón Jódar Masanés
Lluís Campins Bernadas
Tomás Casasín Edo
Juan Carlos Juárez Giménez
Carles Quiñones Ribas
Volume 21 - Issue 5, September-October 2019
ORIGINAL
TOXICITY AND EFFICACY OF THE CETUXIMAB-FOLFOX REGIMEN IN FIRST-LINE OF RAS WILD-TYPE METASTATIC COLORECTAL CANCER
GALLARDO BORGE SARA, SANGRADOR PELLUZ CRISTINA, LÓPEZ-MONTENEGRO SORIA MARÍA ÁNGELES, REDONDO CAPAFONS SUSANA, FERNÁNDEZ PLANA JULEN, NICOLÁS PICÓ JORDI


A 9-year retrospective observational study (January 2009-December 2017) conducted in a 450-bed hospital. The aim of the study was to assess the toxicity and efficacy of the cetuximab-FOLFOX regimen in first-line therapy of RAS wildtype metastatic colorectal cancer in daily clinical practice. The outcomes suggested a similar efficacy to prior published studies and an acceptable safety profile, mainly based on mild-moderate toxicity.

CETUXIMAB – EFFICACY – FOLFOX – TOXICITY



Fill out the form below to buy this article

Name and surname:

DNI/NIF ID/VAT IDENTIFICATION No.:

Contact Email:

Phone:

Address:

Zip code:

City:

Province:

Country:

*I have read and accept the privacy policy
Price : 30,25